It's been a wild roller-coaster ride for Iovance Biotherapeutics (NASDAQ: IOVA). In February, the stock more than doubled in price, then it fell to a 52-week low in July. The stock has since recovered and at recent prices was up 47% for the year.

Can Iovance keep soaring in the years to come, or is its big gain in 2024 more likely to fizzle out? Here's a look at what to expect in the near term from this popular stock.

Iovance Biotherapeutics stock more than doubled in February after the Food and Drug Administration approved Amtagvi, its first drug. Amtagvi is a complicated cellular therapy made of tumor-infiltrating lymphocytes (TILs), a type of immune cell that recognizes and attacks cancer cells.

Continue reading

Source Fool.com